Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMTANASDAQ:MRUSNASDAQ:RYTMNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMTAClementia Pharmaceuticals$26.35$26.35$8.10▼$26.73$1.00B0.64145,059 shs716,706 shsMRUSMerus$56.03-2.7%$44.18$33.19▼$62.98$3.88B0.94946,560 shs1.41 million shsRYTMRhythm Pharmaceuticals$66.26+2.9%$60.17$38.82▼$68.58$4.20B2.36556,229 shs477,975 shsSRPTSarepta Therapeutics$39.16-1.0%$48.86$34.10▼$173.25$3.85B0.852.52 million shs2.02 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMTAClementia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRUSMerus-7.75%+15.14%+32.80%+24.90%+14.34%RYTMRhythm Pharmaceuticals-1.95%+8.06%-0.03%+24.69%+66.90%SRPTSarepta Therapeutics+1.72%+6.20%-37.89%-62.54%-66.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMTAClementia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMRUSMerus2.9157 of 5 stars4.62.00.00.02.61.70.0RYTMRhythm Pharmaceuticals3.9104 of 5 stars3.51.00.04.33.90.80.6SRPTSarepta Therapeutics4.8113 of 5 stars4.42.00.04.23.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMTAClementia Pharmaceuticals 0.00N/AN/AN/AMRUSMerus 3.13Buy$85.8353.18% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$76.6215.63% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$122.61213.12% UpsideCurrent Analyst Ratings BreakdownLatest CMTA, MRUS, SRPT, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/22/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.005/20/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/8/2025SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy$188.00 ➝ $85.005/8/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.005/8/2025SRPTSarepta TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline$50.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.005/7/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$87.00 ➝ $58.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMTAClementia PharmaceuticalsN/AN/AN/AN/A$5.18 per shareN/AMRUSMerus$54.73M70.86N/AN/A$6.17 per share9.08RYTMRhythm Pharmaceuticals$136.86M30.80N/AN/A$2.87 per share23.09SRPTSarepta Therapeutics$2.23B1.72N/AN/A$9.19 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMTAClementia Pharmaceuticals-$58.13M-$7.93N/AN/AN/AN/A-44.73%-41.66%N/AMRUSMerus-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$2.81N/AN/AN/A-230.07%-367.36%-77.47%8/5/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M-$2.6931.333.58N/A7.43%11.00%3.35%8/6/2025 (Estimated)Latest CMTA, MRUS, SRPT, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMTAClementia PharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMTAClementia PharmaceuticalsN/A14.0314.03MRUSMerusN/A8.328.32RYTMRhythm PharmaceuticalsN/A3.493.34SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMTAClementia Pharmaceuticals78.72%MRUSMerus96.14%RYTMRhythm PharmaceuticalsN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCMTAClementia PharmaceuticalsN/AMRUSMerus4.57%RYTMRhythm Pharmaceuticals6.10%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMTAClementia Pharmaceuticals3038.06 millionN/ANot OptionableMRUSMerus3769.21 million65.34 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million58.02 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableCMTA, MRUS, SRPT, and RYTM HeadlinesRecent News About These CompaniesWhy Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?June 5 at 12:36 PM | zacks.comFDA Grants Platform Technology Tag to Sarepta's Gene Therapy VectorJune 5 at 11:06 AM | zacks.comFDA to use new review tool on Sarepta’s gene therapy workJune 4 at 10:17 PM | biopharmadive.comBuy Rating on Sarepta Therapeutics Driven by FDA Platform Technology DesignationJune 4 at 12:47 PM | tipranks.comU.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4June 4 at 9:30 AM | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest UpdateJune 3 at 12:59 PM | marketbeat.com1 Value Stock on Our Buy List and 2 to Approach with CautionJune 2 at 3:26 PM | finance.yahoo.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 1, 2025 | marketbeat.comMackenzie Financial Corp Has $2.83 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 31, 2025 | marketbeat.comStockWatch: Intellia Stumbles on News of Patient’s Severe Liver ToxicityMay 30, 2025 | genengnews.comQ2 Earnings Forecast for SRPT Issued By Zacks ResearchMay 30, 2025 | marketbeat.comResearch Analysts Set Expectations for SRPT Q2 EarningsMay 30, 2025 | americanbankingnews.comD. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 28, 2025 | marketbeat.comWas Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?May 27, 2025 | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $36.39 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $9.13 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 27, 2025 | marketbeat.com46,986 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by Woodline Partners LPMay 26, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Receives "Neutral" Rating from HC WainwrightMay 24, 2025 | marketbeat.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | BenzingaMay 23, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up - Still a Buy?May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMTA, MRUS, SRPT, and RYTM Company DescriptionsClementia Pharmaceuticals NASDAQ:CMTAClementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.Merus NASDAQ:MRUS$56.03 -1.55 (-2.68%) Closing price 03:59 PM EasternExtended Trading$56.05 +0.02 (+0.03%) As of 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Rhythm Pharmaceuticals NASDAQ:RYTM$66.26 +1.87 (+2.90%) Closing price 03:59 PM EasternExtended Trading$66.19 -0.07 (-0.10%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$39.16 -0.38 (-0.97%) Closing price 03:59 PM EasternExtended Trading$39.17 +0.02 (+0.05%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
